A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein-eftilagimod Alpha) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab
The purpose of this study is to determine the safety, tolerability and recommended phase 2 dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients with unresectable or metastatic melanoma.
100 Clinical Results associated with Immutep Australia Pty. Ltd.
0 Patents (Medical) associated with Immutep Australia Pty. Ltd.
100 Deals associated with Immutep Australia Pty. Ltd.
100 Translational Medicine associated with Immutep Australia Pty. Ltd.